We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Port Erin | LSE:PEBI | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 4.00 | 5.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMPEBI
RNS Number : 9138E
Port Erin Biopharma Investments Ltd
22 July 2016
22 July 2016
Port Erin Biopharma Investments Limited
(the "Company")
Net Asset Value calculation to 30 June 2016
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 June 2016 was 9.28 pence per share, including un-invested cash of GBP11,985. The portfolio is valued under IFRS at bid price.
Net Assets stand at GBP2.2 million including Investments of GBP2.19 million. This quarter's NAV represents a decrease of 9.11% from the previous valuation of 10.21 pence per share, which included un-invested cash of GBP10,713. No additional management fee is due to Shellbay Investments Limited.
Hot Features
Premium
Unaudited to 30 June 2016 GBP
Fixed Assets
Investments 2,187,075
Current Assets
Sundry Debtors 7,335
Uninvested cash 11,985
Current Liabilities
Creditors: amounts due (54,197)
-----------------------------
2,152,198
Capital and Reserves
Share Capital 23
Share Premium 1,890,142
Reserves 262,033
-----------------------------
2,152,198
Shares in Issue 23,195,558
Net Asset Value per share 9.28 pence
Portfolio Details
Investments as at 30 Value % of Total Portfolio June 2016 ------------------------- ------------- -------------------- Magna Biopharma Income Fund GBP1,231,912 56.3% Regent Pacific Group GBP249,594 11.4% Summit Corporation GBP218,291 10.0% Other quoted holdings GBP85,407 3.9% Other unquoted holdings GBP401,871 18.4% Total GBP2,187,075 100.0% ------------------------- ------------- --------------------
For further information, please contact:
Port Erin Biopharma Northland Capital Peterhouse Capital
Investments Limited Partners Limited Limited
The Company Nomad and Broker Joint Broker
Denham Eke Matthew Johnson Lucy Williams
(+44) (0) 1624 639396 / David Hignell (+44) (0) 207 469
(+44) (0) 203 861 0936
6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
NAVFMGZNKMMGVZM
(END) Dow Jones Newswires
July 22, 2016 02:00 ET (06:00 GMT)
1 Year Port Erin Chart |
1 Month Port Erin Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
